Eicosanoide und Magen-Darm-Trakt

  • B. M. Peskar
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 92)

Zusammenfassung

Eicosanoide sind Derivate mehrfach ungesättigter Fettsäuren, die durch die Einwirkung verschiedener Enzyme gebildet werden. Die durch die Cyclooxigenase synthetisierten Prostaglandine (PG) und Thromboxan A2 sowie die durch die 5-Lipoxigenase gebildeten Leukotriene haben für Physiologie und Pathophysiologie des Gastrointesti-naltrakts besondere Bedeutung erlangt. Dies beruht einerseits darauf, daß diese Arachidonsäure-Metabolite zahlreiche gastrointestinale Funktionen beeinflussen. Andererseits verfügen die verschiedenen Gewebe des Gastrointeslinaltrakts über eine hohe Synthese- und Inaklivicrungskapazilät für Cyclooxigenase- und 5-Lipoxigenase-Derivate der Arachidonsäure. Weiter konnte gezeigt werden, daß verschiedene gastrointestinale Erkrankungen mit einer vom Normalen abweichenden Bildung von Prostaglandinen und/oder Leukotrienen einhergehen, und daß Pharmaka, welche gastrointestinale Wirkungen oder Nebenwirkungen besitzen, in den Arachidonsäure-Stoffwcchsel dieses Organ-Systems eingreifen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahlquist DA, Dozois RR, Zinsmeister AR, Malagelada JR (1983) Duodenal prostaglandin synthesis and acid load in health and in duodenal ulcer disease. Gastroenterology 85:522–529PubMedGoogle Scholar
  2. Basso N,Materia A, Forlini A, Rossi P, Jaffe BM (1983) Gastric mucosal prostaglandin generation in rats with stress ulcer. Adv Prostaglandin Thromboxane Leukotriene Res 12:383–387Google Scholar
  3. Bukhave K, Rask-Madsen J (1980) Saturation kinetics applied to in vitro effects of low prostaglandin E2 and F2α concentrations on ion transport across human jejunal mucosa. Gastroenterology 78:32–42PubMedGoogle Scholar
  4. Buller KJ, Hillier K, Smith CL (im Druck) Eicosanoid synthesis by normal and ulcerated human duodenal mucosa. Br J PharmacolGoogle Scholar
  5. Charlet N, Gallo-Torres HE, Buonameneaux Y, Wills RJ (1985) Prostaglandins and the protection of the gastroduodenal mucosa in humans: A critical review. J Clin Pharmacol 25:564–582PubMedCrossRefGoogle Scholar
  6. Coersmeier C, Wittenberg HR, Aehringhaus U, Dreyling KW, Peskar BM, Brune K, Peskar BA (1985) Die Wirkung entzündungshemmender Pyrazolderivate auf den Arachidonsäuremetabolismus des isoliert perfundierten Herzens und der Magenschleimhaut in vitro. In: Brune K, Lanz R (eds) 100 Jahre Pyrazolone. Urban & Schwarzenberg, München Wien Baltimore, pp 113–126Google Scholar
  7. Dahlen SE, Björk J, Hedqvist P, Arfors KE, Hammarström S, Lindgren JA, Samuelsson B (1981) Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 78:2887–2891CrossRefGoogle Scholar
  8. Dreyling KW, Lange K, Peskar BA, Peskar BM, Release of leukotrienes by rat and human gastric mucosa and its pharmacological modification. Br J Pharmacol (im Druck)Google Scholar
  9. Flower RJ, Vane JR (1972) Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240:410–411PubMedCrossRefGoogle Scholar
  10. Ford-Hutchinson AW, Bray MA, Cunningham FM, Smith MJH (1980) Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leucocytes. Nature 286:264–265PubMedCrossRefGoogle Scholar
  11. Gilat T, Ratan J, Rosen P, Peled Y (1979) Prostaglandins and ulcerative colitis. Gastroenterology 77:1083Google Scholar
  12. Groeger JS, Dazza SJ, Carlon GC, Turnbull AD, Pierrie MK, Howland WS (1982) Prostaglandin therapy in a case of refractory stress ulcer bleading. Crit Care Med 10:486–487PubMedCrossRefGoogle Scholar
  13. Hawkey CJ, Rampton DS (1985) Prostaglandins and the gastrointestinal mucosa: Are they important in its function, disease, or treatment? Gastroenterology 89:1162–1188PubMedGoogle Scholar
  14. Hollander W, Tarnawski A, Gergeley H, Zipser RD (1984) Sucralfate protection of the gastric mucosa against ethanol-induced injury: a prostaglandin-mediated process? Scand J Gastroenterol 19 (Suppl 101): 97–102Google Scholar
  15. Konturek SJ, Kwiecien N, Swierczek J, Olesky J, Sito E, Robert A (1976) Comparison of methylated prostaglandin E2 analogues given orally in the inhibitor of gastric responses to pentagastrin and peptone meal in man. Gastroenterology 70:683–687PubMedGoogle Scholar
  16. Konturek SJ (1984) Actions of nonsteroid antiinflammatory compounds on gastric mucosal integrity and prostaglandin formation in healthy subjects and peptic ulcer patients. In: Rainsford KD, Velo GP (eds) Advances in Inflammation Research, Vol 6. Raven Press, New York, pp 29–37Google Scholar
  17. Lacey ER, Ito S (1982) Microscopic analysis of ethanol damage to rat gastric mucosa after treatment with a prostaglandin. Gastroenterology 83:619–625Google Scholar
  18. Lauritsen K, Hansen J, Ryde M, Rask-Madsen J (1984) Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 86:1496–1500PubMedGoogle Scholar
  19. Lauritsen K, Laursen LS, Havelund T, Bytzer P, Svendsen LB, Rask-Madsen J (1986) Enprostil and ranitidine in duodenal ulcer healing: double blind comparative trial. Brit Med J 292:864–866CrossRefGoogle Scholar
  20. Matuchansky C, Coutror S (1978) The role of prostaglandins in the study of intestinal water and electrolyte transport in man. Biomedicine 28:143–148PubMedGoogle Scholar
  21. Peppercorn MA, Goldman P (1973) Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 64:240–245PubMedGoogle Scholar
  22. Peskar BM (1977) On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs. Biochim. Biophys Acta 487:307–314CrossRefGoogle Scholar
  23. Peskar BM (1983) Effects of carbenoxolone on the gastric mucosal prostaglandin and thromboxane system. Acta gastro-ent belg 46:429–436Google Scholar
  24. Peskar BM, Weiler H, Meyer Ch (1984) Inhibition of prostaglandin production in the gastrointestinal tract by antiinflammatory drugs. In: Rainsford KD, Velo GP (eds) Advances in Inflammation Research, Vol 6. Raven Press, New York, pp 39–50Google Scholar
  25. Peskar BM, Dreyling KW, May B, Theves M, Morgenroth K, Goebell H, Peskar BA (1985) Increased formation of leukotriene B4 and sulfidopeptide-leukotrienes by rectal mucosa of patients with Crohn’s disease and ulcerative colitis. Gut 26: A 542Google Scholar
  26. Peskar BM, Dreyling KW, Peskar BA, May B, Goebell H (im Druck) Enhanced formation of leukotrienes in ulcerative colitis and Crohn’s disease: Inhibition by sulfasalazine and 5-aminosalicylic acid. Agens and ActionsGoogle Scholar
  27. Peskar BM, Lange K, Hoppe U, Peskar BA (1986) Ethanol stimulates formation of leukotriene C4 in rat gastric mucosa. Prostaglandins 31:283–293PubMedGoogle Scholar
  28. Rampton DS, Sladen GE (1981) Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins 21:417–425PubMedGoogle Scholar
  29. Rampton DS, Hawkey CJ (1984) Prostaglandins and ulcerative colitis. Gut 25: 1399–1413PubMedCrossRefGoogle Scholar
  30. Rask-Madsen J, Bukhave K, Madsen PER, Bekker C (1983) Effect of carbenoxolone on gastric prostaglandin E2 levels in patients with peptid ulcer disease following vagal and pentagastrin stimulation. Eur J clin Invest 13:351–356PubMedCrossRefGoogle Scholar
  31. Robert A (1976) Antisecretory, antiulcer, cytoprotective and diarrhaeogenic properties of prostaglandins. Adv Prostaglandin Thromboxane Res 2:507–520PubMedGoogle Scholar
  32. Robert A (1977) The inhibitory effect of prostaglandins on gastric secretion; their possible role in the treatment of gastric hypersecretion and peptic ulcer. In: Glass GBJ (ed) Progress in Gastroenterology. Grune & Stratton, New York San Francisco London, pp 777–801Google Scholar
  33. Robert A (1981) Prostaglandins and the gastrointestinal tract. In: Johnson LR (ed) Physiology of the Gastrointestinal Tract. Raven Press, New York, pp 1407–1434Google Scholar
  34. Robert A, Hanchar AJ, Lancaster C, Nezamis JE (1979a) Prostacyclin inhibits enteropooling and diarrhea. In: Vane JR, Bergström S (eds) Prostacyclin. Raven Press, New York, pp 147–158Google Scholar
  35. Robert A, Nezamis JE, Lancaster C, Hanchar A (1979 b) Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCL, NaOH, hypertonic NaCl and thermal injury. Gastroenterology 77:433–443PubMedGoogle Scholar
  36. Schlegel W, Wenk K, Dollinger HD, Raptis S (1977) Concentrations of prostaglandin A-, E-, and F-like substances in gastric mucosa of normal subjects and of patients with various gastric diseases. Clin Sci Mol Med 52:255–258PubMedGoogle Scholar
  37. Sharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86:453–460PubMedGoogle Scholar
  38. Simmons TC, Weinstein WM, Shapira M, Grossman MI (1981) A therapeutic trial of 15 (R)-15-methyl prostaglandin E2 in rheumatoid arthritis patients with gastroduodenal lesions. Prostaglandins 21 (Suppl): 165–169PubMedGoogle Scholar
  39. Skillman JJ, Lisbon A, Long PS, Silen N (1984) 12(R-) 15-methyl prostaglandin does not prevent gastrointestinal bleeding in seriously ill patients. Am J Surg 147:451–455PubMedCrossRefGoogle Scholar
  40. Smith CL, Hillier K (1983) Duodenal mucosa synthesis of prostaglandins in duodenal ulcer disease. Gut 26:237–240Google Scholar
  41. Soll AH (1981) Physiology of isolated canine parietal cells: receptors and effectors regulating function. In: Johnson LR (ed) Physiology of the gastrointestinal tract. Raven Press, New York, pp 673–691Google Scholar
  42. Szelenyi I, Postius S, Engler J (1983) Evidence for a functional cytoprotective effect produced by antiacids in the rat stomach. European J Pharmacol 88:403–406CrossRefGoogle Scholar
  43. Tarnawski A, Hollander D, Stachura J, Krause WJ, Gergely H (1985) Prostaglandin protection of the gastric mucosa against alcohol injury -a dynamic time-related process. Role of the mucosal proliferative zone. Gastroenterology 88:334–352PubMedCrossRefGoogle Scholar
  44. Van Trappen G, Janssens J, Popiela T, Kulig J, Tytgat GNJ, Huibregtse K, Lambert R, Panchard JP, Robert A (1982) Effect of 15(R)-15 methyl prostaglandin E2 (arbaprostil) on the healing of duodenal ulcers. Gastroenterology 83:357–363Google Scholar
  45. Weiss JB, Peskin GW, Isenberg JI (1982) Treatment of haemorrhagic gastritis with 15(R)-15-methyl prostaglandin E2. Report of a case. Gastroenterology 82:558–560PubMedGoogle Scholar
  46. Whittle BJR, Kauffman GL, Moncada S (1981) Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa. Nature 292:472–474PubMedCrossRefGoogle Scholar
  47. Whittle BJR, Oren-Wolman N, Guth PH (1985) Gastric vasoconstrictor actions of leukotriene C4, PGF2α , and thromboxane mumetic U-46619 on rat submucosal microcirculation in vivo. Am J Physiol 248:G580–586PubMedGoogle Scholar
  48. Wright JP, Young GO, Klaff LJ, Weerss LA, Price SK, Marks IN (1982) Gastric mucosal prostaglandin E levels in patients with gastric ulcer disease and carcinoma. Gastroenterology 82:263–267PubMedGoogle Scholar

Copyright information

© J. F. Bergmann Verlag, München 1986

Authors and Affiliations

  • B. M. Peskar
    • 1
  1. 1.Arbeitsgruppe für Experimentelle Klinische MedizinRuhr-UniversitätBochumDeutschland

Personalised recommendations